ORKA Oruka Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:06
Apr 27
Apr 27
Speaker mentions having opinions on ORKA's launch setup but does not state direction or reasoning; merely acknowledges a pending discussion.
LOW
15:40
Apr 27
Apr 27
Short ORKA due to lack of competitive differentiation against entrenched biosimilars and branded alternatives; implied exit value is too low versus S&P returns.
MED
15:35
Apr 27
Apr 27
Short $ORKA due to unfavorable competitive landscape (safer biosimilars, entrenched brands) and unattractive risk/reward for a post-P3 exit compared to S&P returns.
MED
15:12
Apr 27
Apr 27
Adam May asks for a counter-pitch on ORKA at a $6B valuation without expressing his own forward-looking directional view.
LOW
13:09
Apr 27
Apr 27
Short ORKA based on speaker’s claimed track record of successful shorts in similar names (NTLA, HIMS, VKTX, IOVA).
MED
12:02
Apr 27
Apr 27
Doctor reports clinical success with an existing biosimilar, implying ORKA’s Phase 3 readout is still pending; no directional trade view stated.
LOW
11:35
Apr 27
Apr 27
Short ORKA based on a medical professional's direct clinical experience that existing psoriasis treatments are already highly effective, undermining the need for ORKA's offering.
MED
11:14
Apr 27
Apr 27
Short ORKA due to phase 2a data that merely matches existing therapies (Skyrizi, Bimzelx) while facing biosimilar competition and a $7B market cap that implies unjustified premium for a heavily served indication.
HIGH
18:23
Apr 26
Apr 26
Buy ORKA ahead of tomorrow's Phase 2a data; speaker expects positive readout on PASI100 response rate based on proven IL23p19 efficacy, though valuation near $5B adds risk.
HIGH
About ORKA Analyst Coverage
Buzzberg tracks ORKA (Oruka Therapeutics, Inc. Common Stock) across 1 sources. 1 bullish vs 5 bearish calls from 1 analysts. Sentiment: mixed to bearish. 9 total trade ideas tracked.